Iovance Biotherapeutics (IOVA) grants 90,316 deferred stock units to director
Rhea-AI Filing Summary
Maynard Ryan D reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. director Ryan D. Maynard received a grant of 90,316 deferred restricted stock units, each tied to one share of common stock. The award was made under the company’s 2018 Equity Incentive Plan.
The units vest if he continues providing service until the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Even after vesting, settlement in common stock is deferred until the earlier of three months after he leaves the board or ceases service due to death or disability, a qualifying change in control, or ten years from the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Maynard Ryan D
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Restricted Stock Unit | 90,316 | $0.00 | $0.00 |
Holdings After Transaction:
Deferred Restricted Stock Unit — 90,316 shares (Direct)
Footnotes (2)
- F1. Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
- F2. Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.
Key Figures
Deferred RSU grant: 90,316 units
Post-transaction DRSU holdings: 90,316 units
DRSU-to-share ratio: 1 unit : 1 share
+2 more
5 metrics
Deferred RSU grant
90,316 units
Deferred restricted stock units granted to director on transaction date
Post-transaction DRSU holdings
90,316 units
Total deferred restricted stock units held after this grant
DRSU-to-share ratio
1 unit : 1 share
Each DRSU represents one share of common stock
Plan source
2018 Equity Incentive Plan
Grant made under company’s 2018 Equity Incentive Plan, as amended
Maximum deferral period
10 years
Settlement deferred until up to ten years from transaction date if earlier events do not occur
Key Terms
Deferred Restricted Stock Unit, 2018 Equity Incentive Plan, change in control, Board of Directors
4 terms
Deferred Restricted Stock Unit financial
"Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share"
2018 Equity Incentive Plan financial
"granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended)"
change in control financial
"a change in control (as defined in the DRSU agreement)"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Board of Directors financial
"after the Reporting Person's resignation or removal from the Board of Directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
FAQ
What insider transaction did IOVANCE BIOTHERAPEUTICS (IOVA) report for Ryan D. Maynard?
IOVANCE BIOTHERAPEUTICS reported that director Ryan D. Maynard received 90,316 deferred restricted stock units. Each unit represents a right to receive one share of common stock, granted as director compensation under the company’s 2018 Equity Incentive Plan.
How many deferred restricted stock units did IOVA grant to director Ryan D. Maynard?
Ryan D. Maynard was granted 90,316 deferred restricted stock units. These units are a form of equity compensation that, upon settlement, convert into an equal number of IOVANCE BIOTHERAPEUTICS common shares, subject to vesting and deferral conditions.
When do Ryan D. Maynard’s IOVA deferred restricted stock units vest?
The deferred restricted stock units vest if Maynard continues providing service until the earlier of the first anniversary of the grant date or the day before IOVANCE BIOTHERAPEUTICS’ next annual shareholder meeting, according to the award’s service-based vesting terms.
What does each IOVA deferred restricted stock unit granted to Ryan D. Maynard represent?
Each deferred restricted stock unit represents a contingent right to receive one share of IOVANCE BIOTHERAPEUTICS common stock. The rights are granted under the company’s 2018 Equity Incentive Plan and are subject to specified vesting and settlement conditions.
Is Ryan D. Maynard’s IOVA Form 4 transaction a market purchase or sale?
The Form 4 shows a grant of deferred restricted stock units, not a market trade. The transaction code is an award acquisition, so no shares were bought or sold on the open market in this transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
